Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;25(3):508-519.
doi: 10.1007/s11102-022-01221-3. Epub 2022 Apr 25.

The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus

Hussam Abou-Al-Shaar  1 , Arka N Mallela  1 , Aneek Patel  1 , Rimsha K Shariff  2 , Samuel S Shin  3 , Phillip A Choi  4 , Amir H Faraji  5 , Pouneh K Fazeli  2 , Tina Costacou  6 , Eric W Wang  7 , Juan C Fernandez-Miranda  8 , Carl H Snyderman  7 , Paul A Gardner  1 , Georgios A Zenonos  9
Affiliations

The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus

Hussam Abou-Al-Shaar et al. Pituitary. 2022 Jun.

Abstract

Purpose: To review our institutional experience with the surgical management of prolactinomas through the endoscopic endonasal approach with specific focus on cavernous sinus invasion.

Methods: Clinical and radiographic data were collected retrospectively from the electronic medical record of 78 consecutive patients with prolactinomas undergoing endoscopic endonasal resection from 2002 to 2019. Immediate and late post-operative remission were defined as prolactin < 20 ng/mL within 14 days and 1-year of surgery without adjuvant therapy, respectively. Cavernous sinus invasion was quantified by Knosp score.

Results: A total of 78 patients with prolactinoma, 59% being male, underwent surgical resection with a mean age of 37 ± 13 years. Indications for surgery were medication resistance in 38 patients (48.7%), medication intolerance in 11 (14.1%), and patient preference in 29 (37.2%). Patients with Knosp 0-2 achieved higher immediate remission rates (83.8%) compared to patients with Knosp 3 (58.8%) and Knosp 4 (41.7%) patients (p = 0.003). Long-term remission rates were 48.7% and increased to 71.8% when combined with adjuvant treatments. Knosp 4 prolactinomas had significantly higher tumor volumes, higher preoperative prolactin levels, higher recurrence rates, higher rates of adjuvant therapy utilization, and were more likely to have failed dopamine agonist therapy compared to other tumor grades (p < 0.05). We encountered 18 complications in our series, and no cerebrospinal fluid leaks.

Conclusion: The endoscopic endonasal approach is a safe and effective modality that can be employed in properly selected patients with invasive prolactinomas. It is associated with improved control and remission rates despite cavernous sinus invasion, though at a lower rate than without invasion.

Keywords: Cavernous sinus; Endoscopic endonasal approach; Knosp score; Pituitary adenoma; Prolactinoma.

PubMed Disclaimer

References

    1. Wong A, Eloy JA, Couldwell WT, Liu JK (2015) Update on prolactinomas. Part 1: clinical manifestations and diagnostic challenges. J Clin Neurosci 22:1562–1567 - DOI - PubMed
    1. Wong A, Eloy JA, Couldwell WT, Liu JK (2015) Update on prolactinomas. Part 2: treatment and management strategies. J Clin Neurosci 22:1568–1574 - DOI - PubMed
    1. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11):3574–3579 - DOI - PubMed
    1. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356(1):29–38 - DOI - PubMed
    1. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356(1):39–46 - DOI - PubMed

LinkOut - more resources